Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Henry Schein (HSIC) Buys ABASE, Expands in Animal Health

Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.

    Will Envision Healthcare's Growth Strategies Help the Stock?

    Envision Healthcare (EVHC) is expected to gain from is a number of long term growth strategies.

      Universal Health Grows Inorganically, Rising Costs a Drag

      Universal Health's (UHS) top line grows on solid Acute Care and Behavioral Health platforms. Nevertheless, surging level of debt bothers.

        Cerner Gains Momentum in HCIT Space Amid Tough Competition

        Cerner (CERN) continues to benefit from the ongoing demand for its core solutions and services driven by the HITECH Act.

          Abaxis Well Poised on Solid Prospects, Competition Rife

          Abaxis' (ABAX) new sales and marketing strategies boost investors' confidence.

            IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?

            Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.

              4 Reasons Why Envision Healthcare (EVHC) Looks Dull

              Envision Healthcare continues to suffer from low patient volumes, increased leverage, high operating expense and a weak operating environment.

                Amedisys (AMED) Banks on Personal Care Amid Margin Woes

                Amedisys' (AMED) efforts have helped turn around the Personal Care business.

                  Envision Healthcare Down More Than 50% This Year, Here's Why

                  Envision Healthcare (EVHC) seems to be bogged down by soft patient volumes, increasing expenses and high leverage.

                    Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                    Strength in Hospice and Personal Care businesses offset the weakness in Amedisys' (AMED) Home Health Medicare business.

                      Why Envision Healthcare (EVHC) Could Be Positioned for a Slump

                      Envision Healthcare (EVHC) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.

                        Universal Health Services (UHS) Hits 52-Week Low on Dull Q3

                        Universal Health (UHS) stock suffers on soft third-quarter results and a tepid outlook.

                          Amedisys (AMED) Q3 Earnings Beat, Revenues Miss Estimates

                          At Hospice division, Amedisys (AMED) registered strong growth across all segments in Q3.

                            Envision Healthcare Hits 52-Week Low on Q3 Miss, Grim View (Revised)

                            Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

                              Envision Healthcare Hits 52-Week Low on Q3 Loss, Grim View

                              Envision Healthcare (EVHC) stock suffers on soft third-quarter results and a tepid outlook.

                                What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?

                                DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.

                                  What's in Store for Madrigal (MDGL) This Earnings Season?

                                  Madrigal (MDGL) expects data readout for its lead candidate MGL-3196 on its third-quarter earnings call.

                                    What's in Store for Catalyst (CPRX) This Earnings Season?

                                    Catalyst (CPRX) focus will be on pipeline and regulatory updates at the third-quarter earnings call.

                                      Amedisys' Arm Buys Intercity Home Care, Boosts U.S. Base

                                      Amedisys' (AMED) encouraging efforts put the Personal Care business on growth track. This segment lives up to a strong performance with the integration of several recent tuck-in acquisitions.

                                        Envision Healthcare Continues to Expand Physician Services

                                        Envision Healthcare's (EVHC) numerous acquisitions and management changes are aimed at growing its physician services segment.

                                          Here's Why Mazor Robotics (MZOR) Stock Is Worth a Bet Now

                                          The market is upbeat about Mazor Robotics' (MZOR) recent CE Mark approval for Mazor X Surgical Assurance platform.

                                            STERIS (STE) Rides on Organic Growth, Stiff Contest a Threat

                                            STERIS' (STE) consistent strong organic all-segment growth performance impresses investors. Additionally, growth in free cash flow reserve denotes the company's solid cash position.

                                              Here's Why You Should Invest in Orthofix International Now

                                              Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation.

                                                Can AngioDynamics (ANGO) Spring a Surprise in Q1 Earnings?

                                                AngioDynamics (ANGO) is set to report first-quarter fiscal 2018 (ending Aug 31, 2017) results on Sep 28.

                                                  Omnicell (OMCL) Gains on Product Launches, Global Expansion

                                                  The market is upbeat about Omnicell's (OMCL) recently-launched XT Series Automated Supply Dispensing Cabinet. The company is also expanding its footprint globally.